Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
363
Recruiting, any sponsor type, condition "hepatocellular carcinoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting363
- Completed785
363 trials
Showing 1 to 25, recently updated first.
PfizerPfizer (PFE)
NCT07227012 · 138 participants (planned) · Start Dec 1, 2025 · Primary completion Oct 18, 2027
Drug: PF-08634404; Ipilimumab · For: Carcinoma, Hepatocellular; Hepatocellular Cancer; Hepatocellular Carcinoma and 4 more
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 81 sites in all
Sun Yat-sen UniversityAcademic, hospital or other
NCT07951021 · 42 participants (planned) · Start Oct 15, 2026 · Primary completion Nov 15, 2028
Drug: Lenvatinib; Iparomlimab and Tuvonralimab · For: Hepatocellular Carcinoma; Portal Vein Tumor Thrombus; Hepatic Vein Tumor Thrombus and 1 more
Sites: Guangzhou, China
National Cancer Institute (NCI)NIH
NCT06066138 · 30 participants (planned) · Start Nov 4, 2025 · Primary completion Jan 31, 2027
Drug: Atezolizumab · For: Locally Advanced Alveolar Soft Part Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Locally Advanced Non Small Cell Lung Cancer and 7 more
Sites: Bethesda, Maryland
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Sun Yat-sen UniversityAcademic, hospital or other
NCT07947342 · 43 participants (planned) · Start Oct 20, 2026 · Primary completion Oct 2028
Drug: Pirarubicin · For: Hepatocellular Carcinoma; Liver Neoplasms
Sites: Guangzhou, China
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06600321 · 158 participants (planned) · Start Dec 30, 2024 · Primary completion Sep 30, 2027
Drug: ALN-BCAT; Pembrolizumab · For: Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 23 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT07884877 · 38 participants (planned) · Start Oct 15, 2026 · Primary completion Oct 2028
Drug: Immune checkpoint inhibitor-based therapy · For: Hepatocellular Carcinoma (HCC); Radiotherapy-Induced Immune Priming; Immunotherapy
Sites: Seoul, South Korea
VA Office of Research and DevelopmentFederal agency
NCT05842174 · 93 participants (planned) · Start Apr 1, 2026 · Primary completion Sep 30, 2029
Drug: Hydroxychloroquine; Lipiodol and 1 more · For: Hepatocellular Carcinoma
Sites: Philadelphia, Pennsylvania
Acepodia Biotech, Inc.Industry
NCT07861425 · 70 participants (planned) · Start Nov 2026 · Primary completion May 2030
Drug: ACE723 · For: Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma Metastatic; Hepatocellular Carcinoma Non-Resectable
Sites: Nanjing, China; Shanghai, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05363722 · 50 participants (planned) · Start Mar 6, 2025 · Primary completion Jan 2029
Drug: IBI310(1mg/kg); sintilimab and 1 more · For: Hepatocellular Carcinoma
Sites: Shanghai, China
National Cancer Institute (NCI)NIH
NCT05003895 · 38 participants (planned) · Start Dec 8, 2021 · Primary completion Dec 31, 2026
Drug: Cyclophosphamide; CAR-T cell and 1 more · For: Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Hepatocellular Carcinoma
Sites: Bethesda, Maryland
University of ArizonaAcademic, hospital or other
NCT07627191 · 30 participants (planned) · Start Oct 7, 2026 · Primary completion Jun 30, 2028
Drug: GLP1-RA (semaglutide) · For: Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma
Sites: Tucson, Arizona
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07813572 · 600 participants (planned) · Start Oct 20, 2026 · Primary completion Sep 2031
Drug: ZG005 for Injection; Bevacizumab ( Avastin) and 2 more · For: Hepatocellular Carcinoma
Sites: Nanjing, China
National Cancer Center, KoreaGovernment (non-federal)
NCT07297654 · 50 participants (planned) · Start Apr 27, 2026 · Primary completion May 2028
Drug: Lenvatinib · For: Advanced Hepatocellular Carcinoma
Sites: Goyang-si, South Korea; Guri-si, South Korea; Seongnam-si, South Korea · 6 sites in all
Anwaar SaeedAcademic, hospital or other
NCT06698250 · 40 participants (planned) · Start Dec 18, 2024 · Primary completion Dec 31, 2026
Drug: Zanzalintinib; Durvalumab and 1 more · For: Hepatocellular Carcinoma
Sites: Pittsburgh, Pennsylvania; San Antonio, Texas
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelPivotal-lookingRecruiting
Chen XiaopingAcademic, hospital or other
NCT06420440 · 160 participants (planned) · Start Jun 1, 2024 · Primary completion Dec 31, 2026
Drug: Lenvatinib; Tislelizumab and 1 more · For: HCC
Sites: Nanning, China; Zhengzhou, China; Jingmen, China · 9 sites in all
SEED Therapeutics, Inc.Industry
NCT07197554 · 171 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 31, 2029
Drug: ST-01156 · For: Advanced Solid Tumors; Ewing Sarcoma; Hepatocellular Carcinoma (HCC) and 1 more
Sites: Duarte, California; Newport Beach, California; Boston, Massachusetts · 6 sites in all
Haibo ShaoAcademic, hospital or other
NCT07557914 · 32 participants (planned) · Start Jan 21, 2026 · Primary completion Dec 2029
Drug: Epalrestat; Donafenib + Tislelizumab · For: HCC - Hepatocellular Carcinoma; Diabetes
Sites: Harbin, China; Yanji, China; Shenyang, China · 4 sites in all
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaPivotal-lookingRecruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT07836530 · 492 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 21, 2029
Drug: BGB-B2033; Lenvatinib and 1 more · For: Hepatocellular Carcinoma; Liver Cancer
Sites: South Brisbane, Australia; Grafton, New Zealand
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailurePivotal-lookingRecruiting
CatalYm GmbHIndustry
NCT07219459 · 104 participants (planned) · Start Mar 19, 2026 · Primary completion Sep 2029
Drug: Visugromab RDE (recommended dose for expansion); Nivolumab and 1 more · For: Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma; Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Sites: Irvine, California; Los Angeles, California; Orange, California · 29 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07284121 · 700 participants (planned) · Start Jul 15, 2025 · Primary completion Mar 31, 2027
Drug: Atezolizumab · For: Lung Cancer, Hepatocellular Carcinoma
Sites: Krems, Austria; Linz, Austria; Vienna, Austria · 92 sites in all
VM Discovery, Inc.Industry
NCT07636785 · 111 participants (planned) · Start Jul 16, 2026 · Primary completion May 2031
Drug: VMD-102 · For: Hepatocellular Carcinoma (HCC); Metastatic Uveal Melanoma; Renal Cell Carcinoma (RCC) and 2 more
Sites: Scottsdale, Arizona; Los Angeles, California
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT07807475 · 232 participants (planned) · Start Sep 17, 2026 · Primary completion Sep 15, 2031
Drug: Hyperpolarized 1-13C -Pyruvate · For: Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC; Hepatocellular Carcinoma (HCC)
Sites: Philadelphia, Pennsylvania
- A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCPivotal-lookingRecruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.Industry
NCT07589244 · 66 participants (planned) · Start May 13, 2026 · Primary completion Dec 31, 2028
Drug: VRT106; VRT106 in combination with camrelizumab and apatinib and 1 more · For: HCC
Sites: Guangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.